Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
2.

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.

Decallonne B, Bartholomé E, Delvaux V, D'haeseleer M, El Sankari S, Seeldrayers P, Van Wijmeersch B, Daumerie C.

Acta Neurol Belg. 2018 Jun;118(2):153-159. doi: 10.1007/s13760-018-0883-2. Epub 2018 Jan 25.

3.

Does including the full CVLT-II and BVMT-R improve BICAMS? Evidence from a Belgian (Dutch) validation study.

Costers L, Gielen J, Eelen PL, Schependom JV, Laton J, Remoortel AV, Vanzeir E, Wijmeersch BV, Seeldrayers P, Haelewyck MC, D'Haeseleer M, D'hooghe MB, Langdon D, Nagels G.

Mult Scler Relat Disord. 2017 Nov;18:33-40. doi: 10.1016/j.msard.2017.08.018. Epub 2017 Sep 7.

PMID:
29141818
4.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
5.

Is the Nociception Coma Scale-Revised a Useful Clinical Tool for Managing Pain in Patients With Disorders of Consciousness?

Chatelle C, De Val MD, Catano A, Chaskis C, Seeldrayers P, Laureys S, Biston P, Schnakers C.

Clin J Pain. 2016 Apr;32(4):321-6. doi: 10.1097/AJP.0000000000000259.

PMID:
26035522
6.

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.

van Pesch V, Bartholomé E, Bissay V, Bouquiaux O, Bureau M, Caekebeke J, Debruyne J, Declercq I, Decoo D, Denayer P, De Smet E, D'hooghe M, Dubois B, Dupuis M, Sankari SE, Geens K, Guillaume D, van Landegem W, Lysandropoulos A, de Noordhout AM, Medaer R, Melin A, Peeters K, Ba RP, Retif C, Seeldrayers P, Symons A, Urbain E, Vanderdonckt P, Van Ingelghem E, Vanopdenbosch L, Vanroose E, Van Wijmeersch B, Willekens B, Willems C, Sindic C.

Acta Neurol Belg. 2014 Sep;114(3):167-78. doi: 10.1007/s13760-014-0308-9. Epub 2014 Jun 11.

PMID:
24915752
7.

[Cervical medullar infarction in multileveled discopathy].

Stricker J, Hourrez R, Ikazabo RN, Bruninx G, Seeldrayers P.

Rev Med Brux. 2014 Mar-Apr;35(2):96-8. French.

PMID:
24908948
8.

Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.

De Ridder D, Van Der Aa F, Debruyne J, D'hooghe MB, Dubois B, Guillaume D, Heerings M, Ilsbroukx S, Medaer R, Nagels G, Seeldrayers P, Van Landegem W, Willekens B, Zicot AF.

Clin Neurol Neurosurg. 2013 Oct;115(10):2033-40. doi: 10.1016/j.clineuro.2013.06.018. Epub 2013 Jul 20.

PMID:
23880016
9.

[Cerebral venous thrombosis during acute herpes simplex menigoradicultis. What is the pathophysiological mechanism?].

Mazzoleni R, Piette T, Lucas C, Seeldrayers P.

Rev Neurol (Paris). 2012 Apr;168(4):379-80. doi: 10.1016/j.neurol.2011.08.020. Epub 2012 Mar 3. French. No abstract available.

PMID:
22385973
10.

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.

Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J; FOCUS study group.

Health Qual Life Outcomes. 2010 Nov 15;8:133. doi: 10.1186/1477-7525-8-133.

11.

123I-ioflupane SPECT scan in a patient with Creutzfeldt-Jakob disease.

Mazzoleni R, Vanderheyden JE, Delcourt E, Sellitti E, Noel S, Seeldrayers P.

Acta Neurol Belg. 2010 Mar;110(1):118-9. No abstract available.

PMID:
20514941
12.

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.

Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D; ASIIMS study group.

Mult Scler. 2010 Apr;16(4):455-62. doi: 10.1177/1352458509360547. Epub 2010 Mar 3.

PMID:
20200198
13.

Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis.

Abboud S, Viiri LE, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, Desfontaines P, Gazagnes MD, Laloux P, Peeters A, Seeldrayers P, Lehtimaki T, Karhunen P, Pandolfo M, Laaksonen R.

Eur J Hum Genet. 2008 Aug;16(8):955-60. doi: 10.1038/ejhg.2008.27. Epub 2008 Feb 27.

14.

A unique episode of REM sleep behavior disorder triggered during surgery for Parkinson's disease.

Piette T, Mescola P, Uytdenhoef P, Henriet M, Vanderkelen B, Jacquy J, Seeldrayers P, Godaux E.

J Neurol Sci. 2007 Feb 15;253(1-2):73-6. Epub 2006 Dec 29.

PMID:
17196620
15.

Long-term follow up of glatiramer acetate compassionate use in Belgium.

Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA.

Acta Neurol Belg. 2005 Jun;105(2):81-5.

PMID:
16076061
16.

Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study.

Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P.

J Neurol. 2003 Jun;250(6):693-7.

PMID:
12796831
17.

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernández O, Seeldrayers P, Sørensen P, Margrie S, Rovaris M, Comi G, Filippi M; Early Treatment of Multiple Sclerosis Study Group.

Ann Neurol. 2003 Jun;53(6):718-24.

PMID:
12783417
18.

[Experience of 6 years with multiple sclerosis].

Seeldrayers P.

Bull Mem Acad R Med Belg. 2001;156(6 Pt 2):348-54. French.

PMID:
11928225
19.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group.

Lancet. 2001 May 19;357(9268):1576-82.

PMID:
11377645
20.

Rhythmic cortical and muscle discharges induced by fatigue in corticobasal degeneration.

Manto MU, Jacquy J, Van Bogaert P, Goldman S, Seeldrayers P.

Clin Neurophysiol. 2000 Mar;111(3):496-503.

PMID:
10699413
21.

[The role of interferon beta in the treatment of multiple sclerosis].

Seeldrayers P.

Rev Med Brux. 1999 Sep;20(4):A264-7. Review. French.

PMID:
10523902
22.

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging.

Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV.

Ann Neurol. 1995 Aug;38(2):186-93.

PMID:
7544573
23.

Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.

Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, Hartung HP, Hommes OR, Seeldrayers P, Soelberg-Sorensen P.

Mult Scler. 1995;1 Suppl 1:S24-7.

PMID:
9345394
24.

Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis.

Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV.

Neurology. 1993 Nov;43(11):2331-5.

PMID:
7901809
25.

Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis.

Seeldrayers PA, Syha J, Morrissey SP, Stodal H, Vass K, Jung S, Gneiting T, Lassmann H, Haase A, Hartung HP, et al.

J Neuroimmunol. 1993 Jul;46(1-2):199-206.

PMID:
8360329
26.

Astrocytes support mast cell viability in vitro.

Seeldrayers PA, Levin LA, Johnson D.

J Neuroimmunol. 1992 Feb;36(2-3):239-43.

PMID:
1370670
27.
28.

Treatment of experimental allergic neuritis with nedocromil sodium.

Seeldrayers PA, Yasui D, Weiner HL, Johnson D.

J Neuroimmunol. 1989 Dec;25(2-3):221-6.

PMID:
2479661
29.

[Pathogenesis and treatment of multiple sclerosis. Review and personal results].

Gérard JM, Hildebrand J, Mavroudakis N, Monseu G, Przedborski S, Seeldrayers P, Wautier J, Zegers de Beyl D.

Rev Med Brux. 1988 Sep;9(6):334-9. French. No abstract available.

PMID:
2845554
31.

Role of mast cells in peripheral nervous system demyelination.

Johnson D, Weiner HL, Seeldrayers PA.

Ann N Y Acad Sci. 1988;540:727-8. No abstract available.

PMID:
2974692
32.

Reversible capsulo-tegmental locked-in state as first manifestation of multiple sclerosis.

Seeldrayers PA, Borenstein S, Gerard JM, Flament-Durand J.

J Neurol Sci. 1987 Sep;80(2-3):153-61.

PMID:
3681327
33.

CSF levels of neurotransmitters in Alzheimer-type dementia. Effects of ergoloid mesylate.

Seeldrayers P, Messina D, Desmedt D, Dalesio O, Hildebrand J.

Acta Neurol Scand. 1985 May;71(5):411-4.

PMID:
2409733
34.

Pre- and postoperative changes in serum myelin basic protein immunoreactivity in neurosurgical patients.

Hoyle NR, Seeldrayers PA, Moussa AH, Paul EA, Thomas DG.

J Neurosurg. 1984 Jul;61(1):49-52.

PMID:
6202857
35.

Treatment of neoplastic meningitis.

Seeldrayers P, Hildebrand J.

Eur J Cancer Clin Oncol. 1984 Apr;20(4):449-56. Review. No abstract available.

PMID:
6373301
36.

Myelin basic protein immunoreactivity in serum of neurosurgical patients.

Thomas DG, Hoyle NR, Seeldrayers P.

J Neurol Neurosurg Psychiatry. 1984 Feb;47(2):173-5.

37.

Pre- and post-operative changes in serum immunoglobulin level in neurosurgical patients.

Seeldrayers PA, Hoyle NR, Thomas DG.

Acta Neurochir (Wien). 1984;70(3-4):269-74.

PMID:
6711368
38.

Serum MBP immunoreactivity and immunoglobulin level as markers of tumour type.

Seeldrayers PA, Hoyle NR, Thomas DG.

J Neurooncol. 1984;2(2):141-5.

PMID:
6207275
39.

Diffuse meningocerebral angiodysplasia and adenovirus infection: an improbable relationship.

Flament-Durand J, Noël P, Seeldrayers P, Desprechins M, Depierreux M, Kahn A.

Acta Neuropathol Suppl. 1981;7:365-8.

PMID:
6261520

Supplemental Content

Loading ...
Support Center